Cogent Biosciences vs GRAIL
Cogent Biosciences (COGT), health care, and GRAIL (GRAL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Cogent Biosciences and GRAIL are valued at about the same: $4.8B and $4.8B. Over the past year Cogent Biosciences's share price has moved -17.8% and GRAIL's +29.6%.
Key facts
- Cogent Biosciences market value
- $4.8B
- GRAIL market value
- $4.8B
- GRAIL revenue
- $147.2MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Cogent Biosciences | GRAIL |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.8Bhigher | $4.8Blower |
| Revenue | — | $147.2M |
| Earnings | -$328.9Mhigher | -$408.4Mlower |
| Employees | 258lower | 910higher |
| Total assets | $937.6Mlower | $2.9Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | — | 32.3 |
| P/B | 10.7higher | 1.9lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | — | -382% |
| Balance sheet | ||
| Net assets | $636.4Mlower | $2.6Bhigher |
| Total liabilities | $301.2Mlower | $344.2Mhigher |
| Total debt | $222.9M | — |
| Cash on hand | $312Mhigher | $249.7Mlower |
| Price change | ||
| Today | +1.49%higher | +0.27%lower |
| 1 year | -17.8%lower | +29.6%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Andrew Spokes<0.1% / 3.0%
Cogent Biosciences only (0)
None of the tracked investors.
GRAIL only (2)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Cogent Biosciences / GRAIL). Who owns COGT · Who owns GRAL
More on Cogent Biosciences
Further comparisons
Cogent Biosciences against its closest peers
GRAIL against its closest peers
Learn
Questions and answers
Which is bigger, Cogent Biosciences or GRAIL?
By market value, Cogent Biosciences is the larger: $4.8B against $4.8B for GRAIL.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Cogent Biosciences and GRAIL?
In their latest 13F filings, Andrew Spokes holds both.
Cite this page
Funkfolio, “Cogent Biosciences vs GRAIL”, data as of 18 November 2026. https://funkfolio.com/compare/cogt-vs-gral
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.